



**Anti-Hemophilic  
FACTOR VIIa (Recombinant) 1IU J7189  
Prior Authorization Request  
Medicare Part B Form**

Instructions: \* Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

<input type="checkbox"/>	<b>NEW START - Start Date:</b> _____	<input type="checkbox"/>	<b>Continuation</b> (within 365 days): Date of last treatment _____
<input type="checkbox"/>	Date Requested _____		
	Requestor _____	Clinic name: _____	Phone _____ / Fax _____

**MEMBER INFORMATION**

\*Name: \_\_\_\_\_ \*ID#: \_\_\_\_\_ \*DOB: \_\_\_\_\_

**PRESCRIBER INFORMATION**

\*Name: \_\_\_\_\_ MD FNP DO NP PA \*Phone: \_\_\_\_\_

\*Address: \_\_\_\_\_ \*Fax: \_\_\_\_\_

**DISPENSING PROVIDER / ADMINISTRATION INFORMATION**

\*Name: \_\_\_\_\_ Phone: \_\_\_\_\_

\*Address: \_\_\_\_\_ Fax: \_\_\_\_\_

**PROCEDURE / PRODUCT INFORMATION**

HCPC Code	Name of Drug <input type="checkbox"/> Self-administered	Dose (Wt: _____ kg Ht: _____ )	Frequency	End Date if known

Chart notes attached. **Other important information:** \_\_\_\_\_

**Diagnosis: ICD10:** \_\_\_\_\_ **Description:** \_\_\_\_\_

Provider attests the diagnosis provided is an FDA-Approved indication for this drug

**CLINICAL INFORMATION**

New Start or Initial Request: (Clinical documentation required for all requests)  
 **Provider has reviewed the attached “Criteria for Approval” and attests the member meets ALL required PA criteria.**  
 If not, please provide **clinical rationale** for formulary exception: \_\_\_\_\_

Continuation Requests: (Clinical documentation required for all requests)  
 **Provider has reviewed the attached “Criteria for Continuation” and attests the member meets ALL required PA Continuation criteria.**  
 Patient had an adequate response or significant improvement while on this medication.  
 If not, please provide clinical rationale for continuing this medication: \_\_\_\_\_

**ACKNOWLEDGEMENT**

**Request By (Signature Required):** \_\_\_\_\_ **Date:** \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties. **THIS AUTHORIZATION IS NOT A GUARANTEE OF PAYMENT. PAYMENT IS BASED ON BENEFITS IN EFFECT AT THE TIME OF SERVICE, MEMBER ELIGIBILITY AND MEDICAL NECESSITY.**

## Prior Authorization Group – Coagulation Factors PA

### Drug Name(s):

**FACTOR VIIa (Recombinant)**

### Criteria for approval of Non-Formulary/Preferred Drug:

1. Prescribed for an approved FDA diagnosis (as listed below):
2. Treatment purpose:
  - a. Bleeding episodes OR
  - b. Prophylaxis of perioperative hemorrhage
3. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
  - If the member meets all these criteria, they may be approved by the Plan for the requested drug.
  - Quantity limits and Tiering will be determined by the Plan.

### Exclusion Criteria:

**N/A**

### Prescriber Restrictions:

**N/A**

### Coverage Duration:

**Approval will be for 12 months**

### FDA Indications:

#### **Factor VIIa (Recombinant)**

- Acquired hemophilia – Hemorrhage
- Acquired hemophilia - Perioperative hemorrhage; Prophylaxis
- Factor VII deficiency, Congenital - Hemorrhage
- Factor VII deficiency, Congenital - Perioperative hemorrhage; Prophylaxis
- Glanzmann's thrombasthenia - Hemorrhage
- Glanzmann's thrombasthenia - Perioperative hemorrhage; Prophylaxis
- Hemophilia, A or B, with inhibitors - Hemorrhage
- Hemophilia, A or B, with inhibitors - Perioperative hemorrhage; Prophylaxis

### Off-Label Uses:

- Drug action reversal, Anticoagulation
- Postoperative hemorrhage, Cardiac surgery (pediatric only)

### Age Restrictions:

**N/A**

### Other Clinical Consideration:

**N/A**

### Resources:

[https://www.micromedexsolutions.com/micromedex2/librarian/CS/CF3F67/ND\\_PR/evidencexpert/ND\\_P/evidencexpert/DUPLICATIONSHIELDSYNC/3E270F/ND\\_PG/evidencexpert/ND\\_B/evidencexpert/ND\\_AppProduct/evidencexpert/ND\\_T/](https://www.micromedexsolutions.com/micromedex2/librarian/CS/CF3F67/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/3E270F/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/)

For questions or assistance, please contact Customer Service at 1-877-672-8620, daily, 8am – 8pm (PST) (TTY users should call 1-800-735-2900).



## Part B Prior Authorization Guidelines

[evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Coagulation+Factor+VIIa&fromInterSaltBase=true&UserMdxSearchTerm=%24userMdxSearchTerm&>false=null&=null#](https://evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Coagulation+Factor+VIIa&fromInterSaltBase=true&UserMdxSearchTerm=%24userMdxSearchTerm&>false=null&=null#)

Clinical / CMS  
Only